Form 8-K

8-K — Cryoport, Inc.

Accession: 0001104659-26-054942

Filed: 2026-05-04

Period: 2026-05-04

CIK: 0001124524

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — tm2613494d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2613494d1_ex99-1.htm)

GRAPHIC (tm2613494d1_ex99-1img001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2613494d1_8k.htm · Sequence: 1

false

0001124524

2026-05-04

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event

reported): May 4, 2026

CRYOPORT, INC.

(Exact name of registrant as specified in its charter)

Nevada

001-34632

88-0313393

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

112

Westwood Place, Suite

350, Brentwood,

TN 37027

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (949) 470-2300

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction

A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section

12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which

registered

Common Stock, $0.001 par value

CYRX

The NASDAQ Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for

complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02 Results of Operations and Financial Condition.

On May 4, 2026, Cryoport, Inc. (the “Company”)

issued a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of the press release issued

by the Company is attached hereto as Exhibit 99.1.

The information, including the exhibit attached

hereto, in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange

Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed

incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as otherwise expressly stated in

such filing.

Item 9.01.

Financial Statements and Exhibits

(d)

Exhibits.

The following material is filed as an exhibit to this Current Report on Form 8-K:

Exhibit

Number

99.1 Press Release dated May 4, 2026 issued by the Company.

104 Cover Page Interactive Data File (embedded within the inline

XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 4, 2026

Cryoport, Inc.

/s/ Robert Stefanovich

Robert Stefanovich

Chief Financial Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2613494d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

Cryoport

Reports First Quarter 2026 Financial Results

● First

quarter revenue grew 16% year-over-year to $47.8 million

● Commercial

cell and gene therapy (CGT) revenue grew 26% year-over-year to $9.1 million, reflecting continued

expansion in approved CGT programs

● Life

Sciences Services revenue increased 18% year-over-year, led by 21% growth in BioStorage/BioServices

● Life

Sciences Products revenue increased 15% year-over-year, driven by strong demand for cryogenic

systems

● Supporting

a record 766 global clinical trials and 21 commercially approved CGTs as of March 31,

2026

● Company

raises full-year revenue guidance to $192 million - $196 million

NASHVILLE,

Tennessee, May 4, 2026, - Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport” or the “Company”), a leading

global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results

for its first quarter (Q1) of 2026.

Jerrell

Shelton, CEO of Cryoport, commented, “Cryoport delivered a strong start to 2026 with first-quarter revenue of $47.8 million, up

16% year-over-year, reflecting a continuation of our momentum over the past several quarters across our integrated services and products

platform. Revenue in support of commercial Cell and Gene Therapies (CGT) grew 26% to $9.1 million, while clinical trial support revenue

grew 18% to $12.9 million. We continue to support one of the industry’s broadest CGT pipelines, and our leadership across both

clinical and commercial programs positions us well for sustainable growth.

“Our

Life Sciences Services segment delivered another strong quarter, with revenue increasing 18% year-over-year, including 21% growth in

BioStorage/BioServices. This performance reflects the increasing scope and complexity of the Cell & Gene Therapy programs we

support and underscores the critical role we play in supporting our clients with our integrated, temperature-controlled supply chain

services.

“Our

Life Sciences Products segment also performed very well, generating 15% revenue growth, driven by global demand for MVE Biological Solutions’

cryogenic systems. MVE continues to innovate and further solidify its position as the global leader in high-quality cryogenic systems.

“This

growth across both our reporting segments, combined with solid gross margins and continued operational discipline, drove a $2.2 million

year-over-year improvement in adjusted EBITDA from continuing operations, advancing us meaningfully along our “pathway to profitability.”

“Looking

ahead, we see multiple growth catalysts extending beyond 2026, including the planned launch of BioServices operations at our Global Supply

Chain Center in Paris, France in the third quarter, and the planned opening of our new Global Supply Chain Center in Santa Ana, California

in the fourth quarter. These strategic investments expand our global footprint in key geographies and further strengthen our ability

to support the advancement and commercialization of life-saving therapies globally. Reflecting on our strong performance in the first

quarter and increased visibility into the remainder of the year, we are raising our full-year revenue guidance to $192 million to $196

million,” concluded Mr. Shelton.

The

following table presents Q1 2026 revenue compared with Q1 2025:

Cryoport,

Inc. and Subsidiaries

Revenue

Three

Months Ended

March 31,

(unaudited)

(in thousands)

2026

2025

Change

Life Sciences Services

$ 26,898

$ 22,865

18 %

BioLogistics Solutions

21,668

18,531

17 %

BioStorage/BioServices

5,230

4,334

21 %

Life Sciences Products

$ 20,900

$ 18,175

15 %

Total Revenue

$ 47,798

$ 41,040

16 %

BioLogistics

Solutions revenue increased 17% year-over-year in Q1 2026, driven by increasing customer activity, continued commercial product maturation,

and clinical advancement within the CGT market. BioStorage/BioServices revenue grew 21% year-over-year, reflecting strong demand for

our expanded, integrated services offering, which provides seamless, secure handling of temperature-sensitive materials across our global

network.

Revenue

from the support of commercial CGTs increased 26% year-over-year to $9.1 million and as of March 31, 2026, the number of commercial

therapies we support increased to 21.

of March 31, 2026, Cryoport supported a total of 766 global clinical trials, a net increase of 55 clinical trials over March 31,

2025, with 91 of these clinical trials in Phase 3. The number of trials by phase and region are as follows:

Cryoport

Supported Clinical Trials by Phase

March

31,

Clinical

Trials

2024

2025

2026

Phase 1

286

304

318

Phase 2

312

328

357

Phase 3

Total

675

711

766

Cryoport

Supported Clinical Trials by Region

March

31,

Clinical

Trials

2024

2025

2026

Americas

518

544

569

EMEA

112

118

143

APAC

Total

675

711

766

Q1 2026, four Biologics License Applications (BLA) / Marketing Authorization Applications (MAA) filings occurred. During the first quarter,

Cryoport’s customer, Rocket Pharmaceuticals, received U.S. Food and Drug Administration (FDA) accelerated approval for their gene

therapy KRESLADI™ for the treatment of pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I). Severe LAD-I is

an ultra-rare, life-threatening pediatric genetic immunodeficiency characterized by recurrent infections and high early-childhood mortality

without treatment. For the balance of 2026, we anticipate another 10 possible BLA/MAA application filings and 8 additional new therapy

approvals.

Operational

milestones

Life

Sciences Services

● BioServices

launch at our Global Supply Chain Center in Paris, France, expected in Q3, 2026.

● Continued

progress toward the launch of our state-of-the-art Global Supply Chain Center in Santa Ana,

California, expected in Q4, 2026.

● First

cryopreserved clinical trial patient materials shipped in Q1 for two of our clients at our

IntegriCell® facilities in Belgium and the U.S.

● Cryoport

Systems named Best Logistics & Supply Chain Management Supplier - Digital Technology &

Software at the 2026 Asia Pacific Biopharma Excellence Awards in Singapore.

Life

Sciences Products

● MVE

Biological Solutions (MVE) introduced its new Fusion® 800 Series, the next

evolution of MVE’s patented, award-winning Fusion technology, a self-sustaining cryogenic

freezer that eliminates the need for a continuous liquid nitrogen (LN₂) supply feed,

delivering exceptional reliability, safety, and sustainability in a compact footprint designed

for space-constrained environments.

● Release

of MVE HE (High Efficiency) cryogenic storage systems series integrated with the new MVE

CryoVerse™ Connect Controller platform.

Financial

Highlights

June 11, 2025, the Company completed the divestiture of its CRYOPDP specialty courier business to DHL Group as part of a strategic

partnership. The results of CRYOPDP, a former business within Cryoport’s Life Sciences Services segment, are presented as discontinued

operations for all periods and are excluded from the non-GAAP financial measures in this release.

Revenue

● Total

revenue for Q1 2026 was $47.8 million, compared to $41.0 million for Q1 2025, a year-over-year

increase of 16%, or $6.8 million.

o Life Sciences Services revenue for Q1

2026 (representing 56% of our total revenue) was $26.9 million, compared to $22.9 million

for Q1 2025, up 18% year-over-year, including BioStorage/BioServices revenue of $5.2 million,

up 21% year-over-year.

o Life Sciences Products revenue for Q1

2026 (representing 44% of our total revenue) was $20.9 million, compared to $18.2 million

for Q1 2025, up 15% year-over-year.

Gross

Margin

● Total

gross margin was 45.8% for Q1 2026, compared to 45.4% for Q1 2025.

o Gross margin for Life Sciences Services

was 48.9% for Q1 2026, compared to 47.9% for Q1 2025.

o Gross margin for Life Sciences Products

was 41.9% for Q1 2026, compared to 42.3% for Q1 2025.

Operating

Costs and Expenses

● Operating

costs and expenses were $31.5 million for Q1 2026, compared to $25.8 million for Q1 2025.

Loss

from Continuing Operations

● Loss

from continuing operations was $9.4 million for Q1 2026, compared to a loss of $6.7 million

for Q1 2025.

Net

Loss – including Discontinued Operations

● Net

loss was $10.5 million for Q1 2026, compared to net loss of $12.0 million for Q1 2025.

● Net

loss attributable to common stockholders for Q1 2026 was $12.5 million, or $0.25 per share,

compared to net loss attributable to common stockholders of $14.0 million, or $0.28 per share

for Q1 2025.

Adjusted

EBITDA from Continuing Operations

● Adjusted

EBITDA from continuing operations was a negative $0.6 million for Q1 2026, compared to a

negative $2.8 million for Q1 2025.

Cash,

Cash equivalents, and Short-Term Investments

● Cryoport

held $403.6 million in cash, cash equivalents, and short-term investments as of March 31,

2026.

Note:

All reconciliations of GAAP to adjusted (non-GAAP) figures above are detailed in the reconciliation tables included later in the press

release.

Additional

Information

Further

information on Cryoport’s financial results is included in the attached condensed consolidated balance sheets and statements of

operations, and additional explanations of Cryoport’s financial performance are provided in the Company’s Quarterly Report

on Form 10-Q for the quarter ended March 31, 2026, which is expected to be filed with the SEC on May 4, 2026. Additionally,

the full report will be available in the SEC Filings section of the Investor Relations section of Cryoport’s website at www.cryoportinc.com.

Earnings

Conference Call Information

IMPORTANT

INFORMATION: In addition to the earnings release, a document titled “Cryoport First Quarter 2026 in Review”, providing

a review of Cryoport’s business update, will be issued at 4:05 p.m. ET on Monday, May 4, 2026. The document is designed

to be read in advance of the questions and answers conference call and will be accessible at https://ir.cryoportinc.com/news-events/ir-calendar.

Cryoport

management will host a conference call at 5:00 p.m. ET on May 4, 2026. The conference call will be in the format of a questions

and answers session and will address any queries investors have regarding the Company’s reported results. A slide deck will accompany

the call.

Conference

Call Information

Date:

Monday, May 4,

2026

Time:

5:00 p.m. ET

Dial-in numbers:

1-800-717-1738 (U.S.), 1-646-307-1865 (International)

Confirmation code:

Request the “Cryoport

Call” or Conference ID: 1191652

Live

webcast:

‘Investor

Relations’ section at www.cryoportinc.com or click here.

Please

allow 10 minutes prior to the call to visit this site to download and install any necessary audio software.

The

questions and answers call will be recorded and available approximately three hours after completion of the live event in the Investor

Relations section of the Company's website at www.cryoportinc.com for a limited time. To access the replay of the questions and

answers click here. A dial-in replay of the call will also be available to those interested, until May 11, 2026. To access

the replay, dial 1-844-512-2921 (United States) or 1-412-317-6671 (International) and enter replay entry code: 1191652#.

About

Cryoport, Inc.

(Nasdaq: CYRX) is a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, with an

emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations

(CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability

across the temperature-controlled supply chain for the life sciences. Our integrated supply chain platform includes the Cryoportal®

Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices,

cryopreservation services, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands

of the life sciences. With innovation, regulatory compliance, and agility at our core, we are "Enabling the Future of Medicine™."

Headquartered

in Nashville, Tennessee, our company maintains a strong global presence with operations across the Americas, EMEA, and APAC.

For

more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport

on X, formerly known as Twitter at https://x.com/cryoport for live updates.

Forward-Looking

Statements

in this press release which are not purely historical, including statements regarding the Company's intentions, hopes, beliefs, expectations,

representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities

Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to the Company's industry,

business, long-term growth prospects, plans, strategies, acquisitions, future financial results and financial condition, such as the

Company's outlook and guidance for full-year 2026 revenue and the related assumptions and factors expected to drive revenue, projected

growth trends in the markets in which the Company operates, the Company's plans and expectations regarding the launch of new products

and services, such as the expected timing and benefits of such products and services launches, the Company’s expectations about

future benefits of its acquisitions, and anticipated regulatory filings, approvals, label/geographic expansions or moves to earlier lines

of treatment approved with respect to the products of the Company's clients. Forward-looking statements also include those related to

the Company’s expectations about future benefits relating to the CRYOPDP divestiture and strategic partnership with DHL (collectively,

the “DHL Transaction”), the Company’s plans regarding its Global Supply Chain Centers, including expected timing of

future openings, the Company’s plans and expectations relating to its strategic pivot to expand its global partnerships, and the

Company’s expectation of revenue contribution from IntegriCell’s cryopreservation service centers throughout 2026. It is

important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors

that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effects

of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, tariffs and other trade restrictions,

foreign currency fluctuations, trends in the products markets, any U.S federal government shutdown, variations in the Company's cash

flow, market acceptance risks, and technical development risks. Additional risks and uncertainties relating to the DHL Transaction include,

but are not limited to, the risk that any disruption resulting from the DHL Transaction may adversely affect our businesses and business

relationships, including with employees and suppliers. The Company's business could be affected by other factors discussed in the Company's

SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q,

as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the

date hereof and the Company cautions investors not to place undue reliance on these forward-looking statements. Except as required by

law, the Company disclaims any obligation and does not undertake to update or revise any forward-looking statements in this press release.

Cryoport

Investor Contacts:

Todd

Fromer / Scott Eckstein

KCSA

Strategic Communications

cryoport@kcsa.com

Cryoport,

Inc. and Subsidiaries

Condensed

Consolidated Statements of Operations

Three

Months Ended

March 31,

(unaudited)

(in thousands,

except share and per share data)

2026

2025

Revenue

Life Sciences Services

revenue

$ 26,898

$ 22,865

Life Sciences Products revenue

20,900

18,175

Total revenue

47,798

41,040

Cost of revenue:

Cost of services revenue

13,747

11,920

Cost of products revenue

12,138

10,479

Total cost of revenue

25,885

22,399

Gross margin

21,913

18,641

Operating costs and expenses:

Selling, general and administrative

27,620

21,901

Engineering and development

3,907

3,934

Total operating costs and expenses:

31,527

25,835

Loss from operations

(9,614 )

(7,194 )

Other income (expense):

Investment income

3,090

1,573

Interest expense

(432 )

(583 )

Other expense, net

(2,368 )

(300 )

Loss before provision for income

taxes

(9,324 )

(6,504 )

Provision for income taxes

(108 )

(234 )

Loss from continuing operations

$ (9,432 )

$ (6,738 )

Loss from discontinued operations,

net

(1,112 )

(5,243 )

Net loss

$ (10,544 )

$ (11,981 )

Paid-in-kind dividend on Series

C convertible preferred stock

(2,000 )

Net loss attributable to common

stockholders

$ (12,544 )

$ (13,981 )

Net loss per share attributable

to common stockholders - basic and diluted

$ (0.25 )

$ (0.28 )

Weighted average common shares

issued and outstanding - basic and diluted

49,897,817

49,947,012

Cryoport,

Inc. and Subsidiaries

Condensed

Consolidated Balance Sheets

March

31,

December

31,

2026

2025

(in thousands)

(unaudited)

Current

assets

Cash

and cash equivalents

$ 272,912

$ 250,494

Short-term

investments

130,722

160,714

Accounts

receivable, net

39,004

33,359

Inventories

21,750

23,188

Prepaid

expenses and other current assets

6,147

8,419

Total

current assets

470,535

476,174

Property

and equipment, net

89,805

85,448

Operating

lease right-of-use assets

39,299

39,720

Intangible

assets, net

138,721

138,082

Goodwill

22,137

22,400

Deposits

2,046

2,092

Deferred

tax assets

1,066

1,073

Total

assets

$ 763,609

$ 764,989

Current liabilities

Accounts

payable and other accrued expenses

$ 15,937

$ 15,283

Accrued

compensation and related expenses

17,007

12,980

Deferred

revenue

2,314

943

Current

portion of operating lease liabilities

3,641

4,133

Current

portion of finance lease liabilities

419

422

Current

portion of convertible senior notes, net

185,390

185,094

Current

portion of notes payable

159

163

Total

current liabilities

224,867

219,018

Notes

payable, net

1,027

1,087

Operating

lease liabilities, net

39,173

39,078

Finance

lease liabilities, net

680

741

Deferred

tax liabilities

1,580

1,354

Other

long-term liabilities

663

444

Contingent

consideration

630

629

Total

liabilities

268,620

262,351

Total

stockholders' equity

494,989

502,638

Total

liabilities and stockholders' equity

$ 763,609

$ 764,989

Note

Regarding Use of Non-GAAP Financial Measures

supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following

non-GAAP measure of financial performance as defined in Regulation G of the Securities Exchange Act of 1934 is included in this release:

adjusted EBITDA from continuing operations. Non-GAAP financial measures are not calculated in accordance with GAAP, are not based on

any comprehensive set of accounting rules or principles and may be different from non-GAAP financial measures presented by other

companies. Non-GAAP financial measures, including adjusted EBITDA from continuing operations, should not be considered as a substitute

for, or superior to, measures of financial performance prepared in accordance with GAAP.

Adjusted

EBITDA from continuing operations is defined as loss from continuing operations adjusted for net interest expense, income taxes, depreciation

and amortization expense, stock-based compensation expense, acquisition and integration costs, cost reduction initiatives, investment

income, unrealized loss on investments, foreign currency loss, changes in fair value of contingent consideration and charges or gains

resulting from non-recurring events, as applicable.

Management

believes that adjusted EBITDA from continuing operations provides a useful measure of Cryoport's operating results, a meaningful comparison

with historical results and with the results of other companies, and insight into Cryoport's ongoing operating performance. Further,

management and the Company’s board of directors utilize adjusted EBITDA from continuing operations to gain a better understanding

of Cryoport's comparative operating performance from period to period and as a basis for planning and forecasting future periods. Adjusted

EBITDA from continuing operations is also a significant performance measure used by Cryoport in connection with its incentive compensation

programs. Management believes adjusted EBITDA from continuing operations, when read in conjunction with Cryoport's GAAP financials, is

useful to investors because it provides a basis for meaningful period-to-period comparisons of Cryoport's ongoing operating results,

including results of operations, against investor and analyst financial models, helps identify trends in Cryoport's underlying business

and in performing related trend analyses, and it provides a better understanding of how management plans and measures Cryoport's underlying

business.

Cryoport,

Inc. and Subsidiaries

Reconciliation

of GAAP loss from continuing operations to adjusted EBITDA

(unaudited)

Three

Months Ended

March 31,

(in thousands)

2026

2025

GAAP loss from continuing

operations

$ (9,432 )

$ (6,738 )

Non-GAAP adjustments to loss:

Depreciation and amortization

expense

6,402

6,134

Acquisition and integration

costs

—

Cost reduction initiatives

—

216

Investment income

(3,090 )

(1,573 )

Unrealized loss on investments

2,105

193

Foreign currency loss

454

245

Interest expense, net

432

583

Stock-based compensation expense

2,395

3,064

Change in fair value of contingent

consideration

(5,178 )

Income taxes

108

234

Adjusted EBITDA from continuing

operations

$ (611 )

$ (2,819 )

GRAPHIC

Filename: tm2613494d1_ex99-1img001.jpg · Sequence: 6

Binary file (4715 bytes)

Download tm2613494d1_ex99-1img001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

May 04, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 04, 2026

Entity File Number

001-34632

Entity Registrant Name

CRYOPORT, INC.

Entity Central Index Key

0001124524

Entity Tax Identification Number

88-0313393

Entity Incorporation, State or Country Code

Entity Address, Address Line One

112

Westwood Place

Entity Address, Address Line Two

Suite

350

Entity Address, City or Town

Brentwood

Entity Address, State or Province

Entity Address, Postal Zip Code

37027

City Area Code

949

Local Phone Number

470-2300

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.001 par value

Trading Symbol

CYRX

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration